These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28238712)
21. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases. Victoria GS; Zurzolo C J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527 [TBL] [Abstract][Full Text] [Related]
22. Role of autophagy in prion protein-induced neurodegenerative diseases. Yao H; Zhao D; Khan SH; Yang L Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):494-502. PubMed ID: 23459558 [TBL] [Abstract][Full Text] [Related]
23. Neuroglial patterns are shared by cerebella from prion and prion-like disorder affected patients. Garcés M; Guijarro MI; Vargas A; Badiola JJ; Monzón M Mech Ageing Dev; 2019 Dec; 184():111176. PubMed ID: 31689427 [TBL] [Abstract][Full Text] [Related]
24. Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease. Pearce MM Curr Opin Genet Dev; 2017 Jun; 44():149-155. PubMed ID: 28441621 [TBL] [Abstract][Full Text] [Related]
25. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Gaggelli E; Kozlowski H; Valensin D; Valensin G Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441 [No Abstract] [Full Text] [Related]
33. Propagation of pathology through brain networks in neurodegenerative diseases: from molecules to clinical phenotypes. Agosta F; Weiler M; Filippi M CNS Neurosci Ther; 2015 Oct; 21(10):754-67. PubMed ID: 26031656 [TBL] [Abstract][Full Text] [Related]
34. An update on pharmacological approaches to neurodegenerative diseases. Scatena R; Martorana GE; Bottoni P; Botta G; Pastore P; Giardina B Expert Opin Investig Drugs; 2007 Jan; 16(1):59-72. PubMed ID: 17155854 [TBL] [Abstract][Full Text] [Related]
35. Synthetic prions and other human neurodegenerative proteinopathies. Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570 [TBL] [Abstract][Full Text] [Related]
36. Neuroprotective and neurotoxic signaling by the prion protein. Resenberger UK; Winklhofer KF; Tatzelt J Top Curr Chem; 2011; 305():101-19. PubMed ID: 21598098 [TBL] [Abstract][Full Text] [Related]
37. Apoptosis and oxidative stress in neurodegenerative diseases. Radi E; Formichi P; Battisti C; Federico A J Alzheimers Dis; 2014; 42 Suppl 3():S125-52. PubMed ID: 25056458 [TBL] [Abstract][Full Text] [Related]
38. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Walker LC; LeVine H Mol Neurobiol; 2000; 21(1-2):83-95. PubMed ID: 11327151 [TBL] [Abstract][Full Text] [Related]
39. Analysis of miRNA Signatures in Neurodegenerative Prion Disease. Bellingham SA; Hill AF Methods Mol Biol; 2017; 1658():67-80. PubMed ID: 28861783 [TBL] [Abstract][Full Text] [Related]
40. Identification of Major Signaling Pathways in Prion Disease Progression Using Network Analysis. Newaz K; Sriram K; Bera D PLoS One; 2015; 10(12):e0144389. PubMed ID: 26646948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]